Cargando…
Improvement in health-related quality of life after therapy with omeprazole in patients with coronary artery disease and recurrent angina-like chest pain. A double-blind, placebo-controlled trial of the SF-36 survey
BACKGROUND: Many patients with coronary artery disease (CAD) have overlapping gastroenterological causes of recurrent chest pain, mainly due to gastroesophageal reflux (GER) and aspirin-induced gastrointestinal tract damage. These symptoms can be alleviated by proton pump inhibitors (PPIs). The stud...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3186737/ https://www.ncbi.nlm.nih.gov/pubmed/21939510 http://dx.doi.org/10.1186/1477-7525-9-77 |
_version_ | 1782213292942426112 |
---|---|
author | Budzyński, Jacek Pulkowski, Grzegorz Suppan, Karol Fabisiak, Jacek Majer, Marcin Kłopocka, Maria Galus-Pulkowska, Beata Wasielewski, Marcin |
author_facet | Budzyński, Jacek Pulkowski, Grzegorz Suppan, Karol Fabisiak, Jacek Majer, Marcin Kłopocka, Maria Galus-Pulkowska, Beata Wasielewski, Marcin |
author_sort | Budzyński, Jacek |
collection | PubMed |
description | BACKGROUND: Many patients with coronary artery disease (CAD) have overlapping gastroenterological causes of recurrent chest pain, mainly due to gastroesophageal reflux (GER) and aspirin-induced gastrointestinal tract damage. These symptoms can be alleviated by proton pump inhibitors (PPIs). The study addressed whether omeprazole treatment also affects general health-related quality of life (HRQL) in patients with CAD. STUDY: 48 patients with more than 50% narrowing of the coronary arteries on angiography without clinically overt gastrointestinal symptoms were studied. In a double-blind, placebo-controlled, cross-over study design, patients were randomized to take omeprazole 20 mg bid or a placebo for two weeks, and then crossed over to the other study arm. The SF-36 questionnaire was completed before treatment and again after two weeks of therapy. RESULTS: Patients treated with omeprazole in comparison to the subjects taking the placebo had significantly greater values for the SF-36 survey (which relates to both physical and mental health), as well as for bodily pain, general health perception, and physical health. In comparison to the baseline values, therapy with omeprazole led to a significant increase in the three summarized health components: total SF-36; physical and mental health; and in the following detailed health concept scores: physical functioning, limitations due to physical health problems, bodily pain and emotional well-being. CONCLUSIONS: A double dose of omeprazole improved the general HRQL in patients with CAD without severe gastrointestinal symptoms more effectively than the placebo. |
format | Online Article Text |
id | pubmed-3186737 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-31867372011-10-05 Improvement in health-related quality of life after therapy with omeprazole in patients with coronary artery disease and recurrent angina-like chest pain. A double-blind, placebo-controlled trial of the SF-36 survey Budzyński, Jacek Pulkowski, Grzegorz Suppan, Karol Fabisiak, Jacek Majer, Marcin Kłopocka, Maria Galus-Pulkowska, Beata Wasielewski, Marcin Health Qual Life Outcomes Research BACKGROUND: Many patients with coronary artery disease (CAD) have overlapping gastroenterological causes of recurrent chest pain, mainly due to gastroesophageal reflux (GER) and aspirin-induced gastrointestinal tract damage. These symptoms can be alleviated by proton pump inhibitors (PPIs). The study addressed whether omeprazole treatment also affects general health-related quality of life (HRQL) in patients with CAD. STUDY: 48 patients with more than 50% narrowing of the coronary arteries on angiography without clinically overt gastrointestinal symptoms were studied. In a double-blind, placebo-controlled, cross-over study design, patients were randomized to take omeprazole 20 mg bid or a placebo for two weeks, and then crossed over to the other study arm. The SF-36 questionnaire was completed before treatment and again after two weeks of therapy. RESULTS: Patients treated with omeprazole in comparison to the subjects taking the placebo had significantly greater values for the SF-36 survey (which relates to both physical and mental health), as well as for bodily pain, general health perception, and physical health. In comparison to the baseline values, therapy with omeprazole led to a significant increase in the three summarized health components: total SF-36; physical and mental health; and in the following detailed health concept scores: physical functioning, limitations due to physical health problems, bodily pain and emotional well-being. CONCLUSIONS: A double dose of omeprazole improved the general HRQL in patients with CAD without severe gastrointestinal symptoms more effectively than the placebo. BioMed Central 2011-09-22 /pmc/articles/PMC3186737/ /pubmed/21939510 http://dx.doi.org/10.1186/1477-7525-9-77 Text en Copyright ©2011 Budzyński et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Budzyński, Jacek Pulkowski, Grzegorz Suppan, Karol Fabisiak, Jacek Majer, Marcin Kłopocka, Maria Galus-Pulkowska, Beata Wasielewski, Marcin Improvement in health-related quality of life after therapy with omeprazole in patients with coronary artery disease and recurrent angina-like chest pain. A double-blind, placebo-controlled trial of the SF-36 survey |
title | Improvement in health-related quality of life after therapy with omeprazole in patients with coronary artery disease and recurrent angina-like chest pain. A double-blind, placebo-controlled trial of the SF-36 survey |
title_full | Improvement in health-related quality of life after therapy with omeprazole in patients with coronary artery disease and recurrent angina-like chest pain. A double-blind, placebo-controlled trial of the SF-36 survey |
title_fullStr | Improvement in health-related quality of life after therapy with omeprazole in patients with coronary artery disease and recurrent angina-like chest pain. A double-blind, placebo-controlled trial of the SF-36 survey |
title_full_unstemmed | Improvement in health-related quality of life after therapy with omeprazole in patients with coronary artery disease and recurrent angina-like chest pain. A double-blind, placebo-controlled trial of the SF-36 survey |
title_short | Improvement in health-related quality of life after therapy with omeprazole in patients with coronary artery disease and recurrent angina-like chest pain. A double-blind, placebo-controlled trial of the SF-36 survey |
title_sort | improvement in health-related quality of life after therapy with omeprazole in patients with coronary artery disease and recurrent angina-like chest pain. a double-blind, placebo-controlled trial of the sf-36 survey |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3186737/ https://www.ncbi.nlm.nih.gov/pubmed/21939510 http://dx.doi.org/10.1186/1477-7525-9-77 |
work_keys_str_mv | AT budzynskijacek improvementinhealthrelatedqualityoflifeaftertherapywithomeprazoleinpatientswithcoronaryarterydiseaseandrecurrentanginalikechestpainadoubleblindplacebocontrolledtrialofthesf36survey AT pulkowskigrzegorz improvementinhealthrelatedqualityoflifeaftertherapywithomeprazoleinpatientswithcoronaryarterydiseaseandrecurrentanginalikechestpainadoubleblindplacebocontrolledtrialofthesf36survey AT suppankarol improvementinhealthrelatedqualityoflifeaftertherapywithomeprazoleinpatientswithcoronaryarterydiseaseandrecurrentanginalikechestpainadoubleblindplacebocontrolledtrialofthesf36survey AT fabisiakjacek improvementinhealthrelatedqualityoflifeaftertherapywithomeprazoleinpatientswithcoronaryarterydiseaseandrecurrentanginalikechestpainadoubleblindplacebocontrolledtrialofthesf36survey AT majermarcin improvementinhealthrelatedqualityoflifeaftertherapywithomeprazoleinpatientswithcoronaryarterydiseaseandrecurrentanginalikechestpainadoubleblindplacebocontrolledtrialofthesf36survey AT kłopockamaria improvementinhealthrelatedqualityoflifeaftertherapywithomeprazoleinpatientswithcoronaryarterydiseaseandrecurrentanginalikechestpainadoubleblindplacebocontrolledtrialofthesf36survey AT galuspulkowskabeata improvementinhealthrelatedqualityoflifeaftertherapywithomeprazoleinpatientswithcoronaryarterydiseaseandrecurrentanginalikechestpainadoubleblindplacebocontrolledtrialofthesf36survey AT wasielewskimarcin improvementinhealthrelatedqualityoflifeaftertherapywithomeprazoleinpatientswithcoronaryarterydiseaseandrecurrentanginalikechestpainadoubleblindplacebocontrolledtrialofthesf36survey |